Volume 31, Number 3—March 2025
Dispatch
Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
Amy L. Leber, Tori Embry, Kathy Everhart, Jeanette Taveras, Sophonie J. Oyeniran, and Huanyu Wang
Table 2
Laboratory characteristics for macrolide-resistant Mycoplasma pneumoniae infections among children after COVID-19 pandemic, by age group, Ohio, USA*
| Characteristics | Total no. | Age group, y |
p value | |||
|---|---|---|---|---|---|---|
| <2 | 2 to <6 | 6 to <10 | >10 | |||
| No. samples tested | 18,035 | 5,288 | 4,373 | 3,401 | 4,973 | NA |
| M. pneumoniae–positive | 2,616 (14.5) | 109 (2.1) | 601 (13.7) | 904 (26.6) | 1,002 (20.1) | <0.0001 |
| Sequenced | 995 (38.0) | 30 (27.5) | 224 (37.3) | 363 (40.2) | 378 (37.7) | NA |
| Macrolide-resistant |
24 (2.4) |
1 (3.3) |
6 (2.7) |
12 (3.3) |
6 (1.6) |
NS |
| No. positive unique patients |
2,469 |
82 |
572 |
865 |
950 |
NA |
| Sex | ||||||
| M | 1,317 (53.3) | 48 (58.5) | 319 (55.8) | 457 (52.8) | 493 (51.9) | NS |
| F |
1,152 (46.7) |
34 (41.4) |
253 (44.2) |
408 (47.2) |
457 (48.1) |
|
| No. medical encounters | 2,478 | 83 | 575 | 866 | 954 | NA |
| Hospitalization | 304 (12.3) | 23 (27.7) | 91 (15.8) | 81 (9.4) | 109 (11.4) | <0.0001 |
| Intensive care unit admission | 53 (2.1) | 6 (7.2) | 19 (3.3) | 14 (1.6) | 14 (1.5) | 0.0009 |
| RP2.1 tested | 359 | 31 | 98 | 100 | 130 | NA |
| Codetection† | 129 (35.9) | 19 (61.3) | 51 (52.0) | 31 (31.0) | 28 (21.5) | <0.0001 |
*Values are no. (%) except as indicated. NA, not applicable; NS, not statistically significant; RP2.1, FilmArray Respiratory Panel version 2.1 (BioFire Diagnostics, https://www.biofiredx.com). †Codetection of M. pneumoniae and other viruses.
Page created: January 15, 2025
Page updated: February 28, 2025
Page reviewed: February 28, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.